Imagion Biosystems announced on ASX that it has received a total of $40,000 for the exercise of 800,000 Listed Options exercisable at 5 cents, expiring
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 6 June 2021. Please click to review the
Imagion Biosystems Limited is pleased to announce that it has received its 2020 R&D tax incentive claim of $2,612,159 from the Australian Taxation Office. This
The document “Results of Annual Meeting” was lodged with ASX on 5 May 2021. Please click to review the full announcement on ASX.
The presentation visuals from the Annual General Meeting of Imagion Biosystems are now available. Please click to view the presentation visuals at ASX.
The presentation visuals from the 28th May 2021 Annual General Meeting are now available. Download here.
The transcript of the chairman’s address to the Annual General Meeting of Shareholders, for the financial year ending December 2020, is now available. Please click
This week Imagion Biosystems has announced we have enrolled our first patient into our first clinical study. This is an important step for our Phase
The Chairman and CEO of Imagion Biosystems, Bob Proulx, recently spoke with The Market Herald on a significant transaction in the molecular imaging market, and several
Imagion Biosystems announced on 10 May 2021 that it has received a total of $44,545.32 for the exercise of options. The total was composed of